CD33 and acute myeloid leukemia: In terms of AML, gemtuzumab ozogamicin (GO), an ADC targeting CD33, has been re-approved and applied as a frontline therapy for CD33-positive AML patients, demonstrating the proof of clinical benefit of ADC in AML treatment [10].